OCA Acquisition Corp. (NASDAQ:OCAXU) (the “Company”) announced today that its board of directors has elected to extend the date by which the Company has to consummate a business combination from July 20, 2022 to January 20, 2023 (the “Extension”), as permitted under the Company’s Amended and Restated Certificate of Incorporation. In connection with the Extension, the Company’s sponsor, OCA Acquisition Holdings LLC, has notified the Company that it intends to deposit an aggregate of $747,500 (representing $0.05 per public share) into the Company’s trust account on or before July 20, 2022. The Extension provides the Company with additional time to complete its initial business combination.
Nanobiotix Announces Presentation Of The Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 In Locally Advanced Head And Neck Cancer Showing Median Progression-Free Survival Of 16.9 Months And Median Overall Survival Of 23.1 Months
Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently high injected-lesion overall
